{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T17:55:34Z","timestamp":1789149334701,"version":"build-2803163510"},"reference-count":61,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.ucl.2019.09.003","type":"journal-article","created":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T12:40:46Z","timestamp":1574167246000},"page":"5-13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Salvage Therapies for Non\u2013muscle-invasive Bladder Cancer: Who Will Respond to Bacillus Calmette-Gu\u00e9rin? Predictors and Nomograms"],"prefix":"10.1016","volume":"47","author":[{"given":"\u00d3scar Rodr\u00edguez","family":"Faba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Pisano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Krajewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Breda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Palou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ucl.2019.09.003_bib1","first-page":"106","article-title":"Cancer statistics, 2006","volume":"56","author":"Jemal","year":"2006","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ucl.2019.09.003_bib2","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.urology.2005.08.066","article-title":"Management of stage T1 tumors of the bladder: international Consensus Panel","volume":"66","author":"Nieder","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.ucl.2019.09.003_bib3","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016","volume":"71","author":"Babjuk","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2019.09.003_bib4","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2009.08.024","article-title":"An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer","volume":"57","author":"Kulkarni","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2019.09.003_bib5","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0090-4295(01)01603-X","article-title":"Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical Bacille Calmette-Guerin: 18-year experience","volume":"59","author":"Pansadoro","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.ucl.2019.09.003_bib6","first-page":"797","article-title":"Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy","volume":"148","author":"Cookson","year":"1992","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2019.09.003_bib7","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1023\/A:1024431519652","article-title":"Evaluation of multiple recurrence events in superficial bladder cancer patients treated with intravesical bacillus Calmette-Guerin therapy using the Andersen-Gill's model","volume":"34","author":"Takashi","year":"2002","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.ucl.2019.09.003_bib8","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1464-410X.2009.09137.x","article-title":"The effect of gender on response to bacillus Calmette-Guerin therapy for patients with non-muscle-invasive urothelial carcinoma of the bladder","volume":"106","author":"Boorjian","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.ucl.2019.09.003_bib9","first-page":"1634","article-title":"The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy","volume":"175","author":"Joudi","year":"2006","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2019.09.003_bib10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12894-016-0122-1","article-title":"Lymphovascular invasion status at transurethral resection of bladder tumors may predict subsequent poor response of T1 tumors to bacillus Calmette-Guerin","volume":"16","author":"Fukumoto","year":"2016","journal-title":"BMC Urol"},{"key":"10.1016\/j.ucl.2019.09.003_bib11","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/bjc.2014.633","article-title":"Reexamining treatment of high-grade T1 bladder cancer according to depth of lamina propria invasion: a prospective trial of 200 patients","volume":"112","author":"Orsola","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ucl.2019.09.003_bib12","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1111\/j.1464-410X.2012.10996.x","article-title":"Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer","volume":"110","author":"van Rhijn","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.ucl.2019.09.003_bib13","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0090-4295(01)00921-9","article-title":"Leukocyturia as a\u00a0predictor of tolerance and efficacy of intravesical BCG maintenance therapy for superficial bladder\u00a0cancer","volume":"57","author":"Saint","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.ucl.2019.09.003_bib14","first-page":"1762","article-title":"Intravesical Bacillus Calmette-Guerin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guerin","volume":"47","author":"Ratliff","year":"1987","journal-title":"Cancer Res"},{"key":"10.1016\/j.ucl.2019.09.003_bib15","first-page":"53","article-title":"Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall","volume":"144","author":"Bohle","year":"1990","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2019.09.003_bib16","doi-asserted-by":"crossref","first-page":"39916","DOI":"10.18632\/oncotarget.9537","article-title":"Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guerin therapy in bladder cancer","volume":"7","author":"Pichler","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ucl.2019.09.003_bib17","first-page":"2660","article-title":"The expression level of ligands for natural killer cell receptors predicts response to bacillus Calmette-Guerin therapy: a pilot study","volume":"178","author":"Yutkin","year":"2007","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2019.09.003_bib18","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.eururo.2009.01.040","article-title":"Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guerin immunotherapy","volume":"55","author":"Ayari","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2019.09.003_bib19","first-page":"1894","article-title":"Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation","volume":"181","author":"Takayama","year":"2009","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2019.09.003_bib20","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.eururo.2017.10.003","article-title":"Predicting response to intravesical Bacillus Calmette-Guerin immunotherapy: are we there yet? a systematic review","volume":"73","author":"Kamat","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2019.09.003_bib21","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.eururo.2008.09.062","article-title":"Protein expression patterns of ezrin are predictors of progression in T1G3 bladder tumours treated with nonmaintenance bacillus Calmette-Guerin","volume":"56","author":"Palou","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2019.09.003_bib22","first-page":"188","article-title":"FGFR3 down-regulation is involved in Bacillus Calmette-Guerin induced bladder tumor growth inhibition","volume":"195","author":"Langle","year":"2016","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2019.09.003_bib23","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3892\/etm.2012.634","article-title":"Prediction of response to bacillus Calmette-Guerin treatment in non-muscle invasive bladder cancer patients through interleukin-6 and interleukin-10 ratio","volume":"4","author":"Cai","year":"2012","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.ucl.2019.09.003_bib24","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1309\/ADJL7E810U1H42BJ","article-title":"Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings","volume":"127","author":"Yoder","year":"2007","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.ucl.2019.09.003_bib25","first-page":"862","article-title":"Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Guerin therapy for bladder cancer: results of a prospective trial","volume":"187","author":"Kamat","year":"2012","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2019.09.003_bib26","doi-asserted-by":"crossref","first-page":"5746","DOI":"10.1200\/JCO.2005.01.598","article-title":"Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival","volume":"23","author":"Leibovici","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ucl.2019.09.003_bib27","doi-asserted-by":"crossref","first-page":"75176","DOI":"10.18632\/oncotarget.12661","article-title":"Genomic characterization of high-risk non-muscle invasive bladder cancer","volume":"7","author":"Meeks","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ucl.2019.09.003_bib28","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.eururo.2011.04.020","article-title":"Evaluation of the methylation status of tumour suppressor genes for predicting bacillus Calmette-Guerin response in patients with T1G3 high-risk bladder tumours","volume":"60","author":"Agundez","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2019.09.003_bib29","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","article-title":"EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive Stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance Bacillus Calmette-Guerin","volume":"69","author":"Cambier","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2019.09.003_bib30","first-page":"2195","article-title":"Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model","volume":"182","author":"Fernandez-Gomez","year":"2009","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2019.09.003_bib31","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/bju.13186","article-title":"Novel fluorescence in situ hybridization-based definition of Bacille Calmette-Guerin (BCG) failure for use in enhancing recruitment into clinical trials of intravesical therapies","volume":"117","author":"Kamat","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.ucl.2019.09.003_bib32","doi-asserted-by":"crossref","first-page":"e12227","DOI":"10.1097\/MD.0000000000012227","article-title":"The role of fluorescence in situ hybridization to predict patient response to intravesical Bacillus Calmette-Guerin therapy for bladder cancer: a diagnostic meta-analysis and systematic review","volume":"97","author":"Bao","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ucl.2019.09.003_bib33","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1440-1827.2011.02694.x","article-title":"Association between the expression pattern of p16, pRb and p53 and the response to intravesical bacillus Calmette-Guerin therapy in patients with urothelial carcinoma in situ of the urinary bladder","volume":"61","author":"Sato","year":"2011","journal-title":"Pathol Int"},{"key":"10.1016\/j.ucl.2019.09.003_bib34","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0090-4295(96)00624-3","article-title":"Significance of p53 overexpression in urinary bladder transitional cell carcinoma in situ before and after bacillus Calmette-Guerin treatment","volume":"49","author":"Ick","year":"1997","journal-title":"Urology"},{"key":"10.1016\/j.ucl.2019.09.003_bib35","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/S0090-4295(03)00236-X","article-title":"Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder","volume":"61","author":"Shariat","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.ucl.2019.09.003_bib36","doi-asserted-by":"crossref","first-page":"45.e23-30","DOI":"10.1016\/j.urolonc.2013.06.008","article-title":"Predicting response to bacillus Calmette-Guerin (BCG) in patients with carcinoma in situ of the bladder","volume":"32","author":"Nunez-Nateras","year":"2014","journal-title":"Urol Oncol"},{"key":"10.1016\/j.ucl.2019.09.003_bib37","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1158\/0008-5472.CAN-04-0374","article-title":"Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guerin-induced antitumor activity","volume":"64","author":"Ludwig","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.ucl.2019.09.003_bib38","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3109\/01913123.2012.728688","article-title":"Prognostic value of tumor-associated macrophages count in human non-muscle-invasive bladder cancer treated by BCG immunotherapy","volume":"37","author":"Ajili","year":"2013","journal-title":"Ultrastruct Pathol"},{"key":"10.1016\/j.ucl.2019.09.003_bib39","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.eururo.2006.06.006","article-title":"HSP90 expression: a new predictive factor for BCG response in stage Ta-T1 grade 3 bladder tumours","volume":"51","author":"Lebret","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2019.09.003_bib40","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.urology.2009.02.053","article-title":"Efficacy of Bacille Calmette-Guerin immunotherapy predicted by expression of antigen-presenting molecules and chemokines","volume":"74","author":"Videira","year":"2009","journal-title":"Urology"},{"key":"10.1016\/j.ucl.2019.09.003_bib41","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/jcp.47.4.309","article-title":"Induction of ICAM 1 expression on bladder tumours by BCG immunotherapy","volume":"47","author":"Jackson","year":"1994","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.ucl.2019.09.003_bib42","first-page":"1636","article-title":"Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall","volume":"147","author":"Prescott","year":"1992","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2019.09.003_bib43","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.eururo.2015.06.023","article-title":"Cytokine panel for response to intravesical therapy (CyPRIT): nomogram of changes in urinary cytokine levels predicts patient response to Bacillus Calmette-Guerin","volume":"69","author":"Kamat","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2019.09.003_bib44","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0302-2838(03)00371-3","article-title":"The side effects of Bacillus Calmette-Guerin in the treatment of Ta T1 bladder cancer do not predict its efficacy: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III trial","volume":"44","author":"Sylvester","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2019.09.003_bib45","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/bju.12844","article-title":"The role of functional polymorphisms in immune response genes as biomarkers of Bacille Calmette-Guerin (BCG) immunotherapy outcome in bladder cancer: establishment of a predictive profile in a Southern Europe population","volume":"116","author":"Lima","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.ucl.2019.09.003_bib46","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1158\/1078-0432.CCR-04-1101","article-title":"Nucleotide excision repair gene polymorphisms and recurrence after treatment for superficial bladder cancer","volume":"11","author":"Gu","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ucl.2019.09.003_bib47","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ccell.2016.05.004","article-title":"Comprehensive transcriptional analysis of early-stage urothelial carcinoma","volume":"30","author":"Hedegaard","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ucl.2019.09.003_bib48","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2019.09.003_bib49","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00345-010-0635-2","article-title":"External validation and applicability of the EORTC risk tables for non-muscle-invasive bladder cancer","volume":"29","author":"Hernandez","year":"2011","journal-title":"World J Urol"},{"key":"10.1016\/j.ucl.2019.09.003_bib50","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.urology.2013.04.007","article-title":"Predicting recurrence and progression in Chinese patients with nonmuscle-invasive bladder cancer using EORTC and CUETO scoring models","volume":"82","author":"Xu","year":"2013","journal-title":"Urology"},{"key":"10.1016\/j.ucl.2019.09.003_bib51","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.canep.2014.02.001","article-title":"Are EORTC risk tables suitable for Chinese patients with non-muscle-invasive bladder cancer?","volume":"38","author":"Ding","year":"2014","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.ucl.2019.09.003_bib52","doi-asserted-by":"crossref","first-page":"643","DOI":"10.4111\/kju.2014.55.10.643","article-title":"Predicting recurrence and progression of non-muscle-invasive bladder cancer in Korean patients: a comparison of the EORTC and CUETO models","volume":"55","author":"Choi","year":"2014","journal-title":"Korean J Urol"},{"key":"10.1016\/j.ucl.2019.09.003_bib53","doi-asserted-by":"crossref","DOI":"10.1007\/s00345-019-02681-2","article-title":"Utility of the EORTC risk tables and CUETO scoring model for predicting recurrence and progression in nonmuscle- invasive bladder cancer patients treated with routine second transurethral resection","author":"Zhang","year":"2019","journal-title":"World J Urol"},{"key":"10.1016\/j.ucl.2019.09.003_bib54","doi-asserted-by":"crossref","first-page":"165","DOI":"10.4111\/kju.2010.51.3.165","article-title":"The efficacy of the EORTC scoring system and risk tables for the prediction of recurrence and progression of non-muscle-invasive bladder cancer after intravesical Bacillus Calmette-Guerin instillation","volume":"51","author":"Seo","year":"2010","journal-title":"Korean J Urol"},{"key":"10.1016\/j.ucl.2019.09.003_bib55","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000336516","article-title":"Recurrence and progression in non-muscle-invasive bladder cancer using EORTC risk tables","volume":"89","author":"Altieri","year":"2012","journal-title":"Urol Int"},{"key":"10.1016\/j.ucl.2019.09.003_bib56","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1111\/iju.12572","volume":"21","author":"Kohjimoto","year":"2014","journal-title":"Int J Urol"},{"key":"10.1016\/j.ucl.2019.09.003_bib57","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1038\/bjc.2013.372","article-title":"Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder","volume":"109","author":"Xylinas","year":"2013","journal-title":"Br J Cancer"},{"issue":"8","key":"10.1016\/j.ucl.2019.09.003_bib58","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.acuro.2019.02.006","article-title":"Validation of the CUETO scoring model for predicting recurrence and progression in T1G3 urothelial carcinoma of the bladder","volume":"43","author":"Krajewski","year":"2019","journal-title":"Actas Urol Esp"},{"key":"10.1016\/j.ucl.2019.09.003_bib59","doi-asserted-by":"crossref","first-page":"E331","DOI":"10.1111\/bju.12026","article-title":"Construction of predictive models for recurrence and progression in\u00a0>1000 patients with non-muscle-invasive bladder cancer (NMIBC) from a single centre","volume":"111","author":"Ali-El-Dein","year":"2013","journal-title":"BJU Int"},{"issue":"9","key":"10.1016\/j.ucl.2019.09.003_bib60","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1007\/s00345-018-2581-3","article-title":"Novel nomograms to predict recurrence and progression in primary non-muscle-invasive bladder cancer: validation of predictive efficacy in comparison with European Organization of Research and Treatment of Cancer scoring system","volume":"37","author":"Kim","year":"2019","journal-title":"World J Urol"},{"key":"10.1016\/j.ucl.2019.09.003_bib61","first-page":"239.e1-7","article-title":"Accurate prediction of progression to muscle-invasive disease in patients with pT1G3 bladder cancer: a clinical decision-making tool","volume":"36","author":"D Andrea","year":"2018","journal-title":"Urol Oncol"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014319300813?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014319300813?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:38:09Z","timestamp":1758807489000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014319300813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0094014319300813"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2019.09.003","relation":{},"ISSN":["0094-0143"],"issn-type":[{"value":"0094-0143","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Salvage Therapies for Non\u2013muscle-invasive Bladder Cancer: Who Will Respond to Bacillus Calmette-Gu\u00e9rin? Predictors and Nomograms","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2019.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}